317318-70-0 | 2-{2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid

Packsize	Purity	Availability	Price	Discounted Price
5mg	97%	in stock	$45.00	$32.00
25mg	97%	in stock	$103.00	$73.00
1g	97%	in stock	$121.00	$85.00
4g	97%	in stock	$314.00	$220.00
5g	97%	in stock	$386.00	$270.00
10g	97%	in stock	$665.00	$466.00
25g	97%	in stock	$1,317.00	$922.00

Description

• Catalog Number: AD50607
• Chemical Name: 2-{2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid
• CAS Number: 317318-70-0
• Molecular Formula: C21H18F3NO3S2
• Molecular Weight: 453.4977
• MDL Number: MFCD09033000
• SMILES: OC(=O)COc1ccc(cc1C)SCc1sc(nc1C)c1ccc(cc1)C(F)(F)F

Computed Properties

• Complexity: 572
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 7
• XLogP3: 5.9

Literature

• Activation of the Constitutive Androstane Receptor by Monophthalates.

  Chemical research in toxicology 20161017

• Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium.

  PloS one 20150101

• Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor α, β, γ subtypes: an in silico approach.

  Journal of applied toxicology : JAT 20140701

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• In vitro toxicological characterization of perfluorinated carboxylic acids with different carbon chain lengths.

  Toxicology letters 20130412

• Role of Peroxisome Proliferator-Activated Receptor β/δ and B-Cell Lymphoma-6 in Regulation of Genes Involved in Metastasis and Migration in Pancreatic Cancer Cells.

  PPAR research 20130101

• Activation of PPARδ prevents endothelial dysfunction induced by overexpression of amyloid-β precursor protein.

  Cardiovascular research 20121201

• PPARδ agonist GW501516 prevents uncoupling of endothelial nitric oxide synthase in cerebral microvessels of hph-1 mice.

  Brain research 20121105

• Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.

  Arteriosclerosis, thrombosis, and vascular biology 20120901

• Activation of PPARδ counteracts angiotensin II-induced ROS generation by inhibiting rac1 translocation in vascular smooth muscle cells.

  Free radical research 20120701

• Reactive oxygen species signaling facilitates FOXO-3a/FBXO-dependent vascular BK channel β1 subunit degradation in diabetic mice.

  Diabetes 20120701

• Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives.

  Bioorganic & medicinal chemistry letters 20120615

• The PPARδ ligand L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ.

  Journal of cellular biochemistry 20120601

• Ligand-activated PPARδ inhibits UVB-induced senescence of human keratinocytes via PTEN-mediated inhibition of superoxide production.

  The Biochemical journal 20120515

• Roles of PPARs in NAFLD: potential therapeutic targets.

  Biochimica et biophysica acta 20120501

• The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.

  Diabetologia 20120301

• Peroxisome proliferator-activated receptor δ confers resistance to peroxisome proliferator-activated receptor γ-induced apoptosis in colorectal cancer cells.

  Oncogene 20120223

• Stem cell antigen-1 deficiency enhances the chemopreventive effect of peroxisome proliferator-activated receptorγ activation.

  Cancer prevention research (Philadelphia, Pa.) 20120101

• Angiopoietin-like 4 mediates PPAR delta effect on lipoprotein lipase-dependent fatty acid uptake but not on beta-oxidation in myotubes.

  PloS one 20120101

• A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1α expression and mitochondrial biogenesis.

  PloS one 20120101

• In vitro responsiveness of human muscle cell peroxisome proliferator-activated receptor δ reflects donors' insulin sensitivity in vivo.

  European journal of clinical investigation 20111201

• Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer.

  Molecular carcinogenesis 20111101

• Activation of peroxisome proliferators-activated receptor δ (PPARδ) promotes blastocyst hatching in mice.

  Molecular human reproduction 20111001

• Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.

  The Journal of clinical endocrinology and metabolism 20111001

• Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes.

  Diabetes 20110701

• PPARδ agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle.

  British journal of pharmacology 20110601

• Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.

  Bioorganic & medicinal chemistry 20110515

• The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

  Endocrinology 20110501

• AP1-dependent repression of TGFα-mediated MMP9 upregulation by PPARδ agonists in keratinocytes.

  Experimental dermatology 20110501

• Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet.

  Drug testing and analysis 20110501

• Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.

  Bioorganic & medicinal chemistry letters 20110415

• Transcriptional up-regulation of antioxidant genes by PPARδ inhibits angiotensin II-induced premature senescence in vascular smooth muscle cells.

  Biochemical and biophysical research communications 20110325

• PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells.

  Biochimica et biophysica acta 20110201

• Endurance factors improve hippocampal neurogenesis and spatial memory in mice.

  Learning & memory (Cold Spring Harbor, N.Y.) 20110201

• Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.

  Bioorganic & medicinal chemistry 20110115

• Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells.

  Journal of cancer research and clinical oncology 20110101

• Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists.

  Bioorganic & medicinal chemistry letters 20110101

• Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation.

  Bioorganic & medicinal chemistry letters 20110101

• Dual acting and pan-PPAR activators as potential anti-diabetic therapies.

  Handbook of experimental pharmacology 20110101

• GW501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice.

  PloS one 20110101

• Angiopoietin-like 4 regulates epidermal differentiation.

  PloS one 20110101

• Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787.

  Molecular pharmacology 20100901

• Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis.

  Immunology 20100801

• Oral administration of a PPAR-delta agonist to rodents worsens, not improves, maximal insulin-stimulated glucose transport in skeletal muscle of different fibers.

  American journal of physiology. Regulatory, integrative and comparative physiology 20100801

• Synthesis of isosteric selenium analog of the PPARbeta/delta agonist GW501516 and comparison of biological activity.

  Bioorganic & medicinal chemistry letters 20100715

• Synthesis and dual PPARalpha/delta agonist effects of 1,4-disubstituted 1,2,3-triazole analogues of GW 501516.

  European journal of medicinal chemistry 20100701

• Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20100505

• The natural protective mechanism against hyperglycemia in vascular endothelial cells: roles of the lipid peroxidation product 4-hydroxydodecadienal and peroxisome proliferator-activated receptor delta.

  Diabetes 20100401

• Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.

  Endocrinology 20100401

• Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice.

  Diabetes, obesity & metabolism 20100301

• Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.

  Journal of medicinal chemistry 20100225

• Rosiglitazone activation of PPARgamma suppresses fractalkine signaling.

  Journal of molecular endocrinology 20100201

• Activation of PPARdelta up-regulates fatty acid oxidation and energy uncoupling genes of mitochondria and reduces palmitate-induced apoptosis in pancreatic beta-cells.

  Biochemical and biophysical research communications 20100115

• Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.

  Journal of medicinal chemistry 20100114

• PPARbeta/delta regulates the human SIRT1 gene transcription via Sp1.

  Endocrine journal 20100101

• Role of peroxisome proliferator-activated receptor beta/delta in chicken adipogenesis.

  Comparative biochemistry and physiology. Part A, Molecular & integrative physiology 20091101

• Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.

  Anticancer research 20090901

• On the mechanism for PPAR agonists to enhance ABCA1 gene expression.

  Atherosclerosis 20090801

• PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle.

  American journal of physiology. Endocrinology and metabolism 20090701

• Selective, potent PPARgamma agonists with cyclopentenone core structure.

  Bioorganic & medicinal chemistry letters 20090401

• Doping control analysis of emerging drugs in human plasma - identification of GW501516, S-107, JTV-519, and S-40503.

  Rapid communications in mass spectrometry : RCM 20090401

• [Doping in the next generation: wringing extra performance from the genotype].

  MMW Fortschritte der Medizin 20090319

• Activation of peroxisome proliferator-activated receptor beta/delta induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha.

  American journal of respiratory cell and molecular biology 20090301

• Regulation of peroxisome proliferator-activated receptor-alpha by MDM2.

  Toxicological sciences : an official journal of the Society of Toxicology 20090301

• Discovery and SAR of para-alkylthiophenoxyacetic acids as potent and selective PPARdelta agonists.

  Bioorganic & medicinal chemistry letters 20090215

• PPARdelta is a ligand-dependent negative regulator of vitamin D3-induced monocyte differentiation.

  Carcinogenesis 20090201

• PPARbeta/delta agonist increases the expression of PGE2 receptor subtype EP4 in human lung carcinoma cells.

  Methods in molecular biology (Clifton, N.J.) 20090101

• Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination.

  Journal of neuroinflammation 20090101

• Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes.

  Molecular pharmacology 20081101

• Are 'exercise pills' the answer to the growing problem of physical inactivity?

  British journal of sports medicine 20081101

• Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta.

  The Journal of biological chemistry 20081024

• The exercise pill--too good to be true?

  The New England journal of medicine 20081023

• Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.

  Bioorganic & medicinal chemistry letters 20081015

• Small molecules can have big effects on endurance.

  Nature chemical biology 20081001

• PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home.

  Expert opinion on investigational drugs 20081001

• Discovery of a novel class of PPARdelta partial agonists.

  Bioorganic & medicinal chemistry letters 20080915

• Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice.

  Basic & clinical pharmacology & toxicology 20080901

• Peroxisome proliferator-activated receptor-delta induces cell proliferation by a cyclin E1-dependent mechanism and is up-regulated in thyroid tumors.

  Cancer research 20080815

• AMPK and PPARdelta agonists are exercise mimetics.

  Cell 20080808

• Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2.

  Diabetes 20080801

• Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.

  Bioorganic & medicinal chemistry 20080801

• Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells.

  Circulation research 20080703

• Endothelial progenitor cells and angiogenesis join the PPARty.

  Circulation research 20080703

• PPARdelta increases expression of the human apolipoprotein A-II gene in human liver cells.

  International journal of molecular medicine 20080601

• In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886).

  Molecular pharmacology 20080501

• Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

  Diabetes 20080201

• Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta.

  The American journal of cardiology 20071203

• Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines.

  Carcinogenesis 20071201

• The PPARdelta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells.

  FEBS letters 20071002

• Design of a partial PPARdelta agonist.

  Bioorganic & medicinal chemistry letters 20070815

• Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARdelta-selective agonists.

  Bioorganic & medicinal chemistry letters 20070801

• Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.

  Bioorganic & medicinal chemistry 20070801

• Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts.

  Cardiovascular research 20070801

• Indanylacetic acids as PPAR-delta activator insulin sensitizers.

  Bioorganic & medicinal chemistry letters 20070801

• Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle.

  The Journal of biological chemistry 20070706

• Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.

  Bioorganic & medicinal chemistry letters 20070701

• Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.

  European journal of pharmacology 20070601

• Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.

  Journal of medicinal chemistry 20070405

• PPARdelta, but not PPARalpha, activates PGC-1alpha gene transcription in muscle.

  Biochemical and biophysical research communications 20070323

• Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.

  Journal of medicinal chemistry 20070308

• Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.

  The Journal of pharmacology and experimental therapeutics 20070301

• Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.

  Journal of medicinal chemistry 20070222

• Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

  Arteriosclerosis, thrombosis, and vascular biology 20070201

• A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth.

  The Journal of biological chemistry 20061110

• Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids.

  Diabetologia 20061101

• BCL-6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells.

  Diabetologia 20061001

• Studies towards the conception of new selective PPARbeta/delta ligands.

  Bioorganic & medicinal chemistry letters 20060901

• Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.

  European journal of pharmacology 20060424

• PPARdelta activator GW-501516 has no acute effect on glucose transport in skeletal muscle.

  American journal of physiology. Endocrinology and metabolism 20060401

• GW-501516 GlaxoSmithKline/Ligand.

  Current opinion in investigational drugs (London, England : 2000) 20060401

• Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.

  Biochemical pharmacology 20060227

• Synthesis of the PPARbeta/delta-selective agonist GW501516 and C4-thiazole-substituted analogs.

  Bioorganic & medicinal chemistry letters 20060101

• Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment.

  Toxicology and applied pharmacology 20051101

• Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta.

  Carcinogenesis 20051001

• Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta.

  The Journal of biological chemistry 20050930

• Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.

  Analytical biochemistry 20050901

• Nanomolar and micromolar effects of 15-deoxy-delta 12,14-prostaglandin J2 on amnion-derived WISH epithelial cells: differential roles of peroxisome proliferator-activated receptors gamma and delta and nuclear factor kappa B.

  Molecular pharmacology 20050701

• Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.

  Neuropharmacology 20050601

• Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys.

  Journal of lipid research 20050501

• Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.

  Cancer research 20050501

• Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta.

  Diabetes 20050401

• Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1.

  Journal of lipid research 20050301

• Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.

  Arthritis and rheumatism 20050301

• PPAR delta: an uncompletely known nuclear receptor.

  Diabetes & metabolism 20050201

• Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms.

  Nuclear receptor 20050101

• [Activation of 'fat burning sensor' peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome].

  Seikagaku. The Journal of Japanese Biochemical Society 20040601

• The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.

  Molecular endocrinology (Baltimore, Md.) 20031201

• A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta.

  The Journal of organic chemistry 20031114

• Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.

  Bioorganic & medicinal chemistry letters 20030505

• A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.

  Proceedings of the National Academy of Sciences of the United States of America 20010424